Summary
The IL-12 family of cytokines comprises the only heterodimeric cytokines mediating diverse functional effects. We previously observed a bi-modal IL-12p70 response to LPS in healthy donors of the Milieu Interieur cohort. Herein, we demonstrate that IFNβ expression serves as an upstream determinant of variable IL-12p70 production. Integrative modelling of proteomic, genetic, epigenomic and cellular data confirmed IFNβ as key for regulation of LPS induced IL12A and IL-12p70 variability. The clinical relevance was supported by reduced and variable IL-12p70 responses in individuals infected with the hepatitis C virus (HCV), and findings that IFN-based therapy for HCV is more likely to fail in those patients with dysregulated pre-treatment IL-12p70 responses. In sum, our systems immunology approach has defined a better understanding of IL-12p70 and IFNβ in healthy and infected persons, providing insights into how common genetic and epigenetic variation may impact immune responses to bacterial infection in health and disease.
Competing Interest Statement
MLA is a current employee of Insitro, who had no influence on the study design or reporting. DD has received grant support in the past from Myriad RBM and Roche Genentech but not in the context of this study. The other authors declare no competing interests.
Clinical Trial
NCT01699893 and NCT03905993 for Milieu Interieur, NTC03925272 for CoSImmGeEn. C10-08 was not registered in clinical trials.gov as this was not the norm at the time of the study (2010).
Clinical Protocols
http://www.milieuinterieur.fr/en/clinical-protocol
Funding Statement
This study was funded with support from the French Governments Investissement dAvenir Program, Laboratoire Excellence Milieu Interieur Grant ANR-10-LABX-69-01 and by an Agence National de Recherche foundation grant (CE17001002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The majority of healthy donor samples came from the Milieur Interieur Cohort, which was approved by the Comite de Protection des Personnes, Ouest 6 (Committee for the protection of persons) on June 13th, 2012 and by French Agence nationale de securite du medicament (ANSM) on June 22nd, 2012. The study is sponsored by Institut Pasteur (Pasteur ID-RCB Number: 2012.A00238.35), and was conducted as a single centre interventional study without an investigational product. The original protocol was registered under ClinicalTrials.gov (study NCT01699893). The samples and data used in this study were formally established as the Milieu Interieur biocollection (study NCT03905993), with approvals by the Comite de Protection des Personnes, Sud Mediterranee and the Commission nationale de linformatique et des libertes (CNIL) on April 11, 2018. Additional healthy donor samples came from the CoSImmGeEn cohort which received ethical committee approval, from the Institut Pasteur (Comite de Protection des Personnes) institutional review board (IRB). CoSImmGen healthy volunteer collections have been declared to the French Ministry of Research (DC.2008.68, DC.2009.1067 and DC.2012.1698). HCV patients were sampled as part of a prospective study (C10.08) sponsored by the Institut National de la Sante et de la Recherche Medicale (Inserm) and by the Agence Nationale de Recherche sur le Sida et les Hepatites Virales (ANRS.C10.08). Approval of the study was obtained from the French Comite de protection des personnes (CPP IDF II) in 2010, August 2nd, and all patients gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The genotype data reported in this paper have been deposited in the European Genome-Phenome Archive (EGA; accession no. EGAS00001002460).
